Neurohormonal axis in patients with pulmonary arterial hypertension: Friend or foe?

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 1, 2013, Pages 14-19

  De Man, Frances S ^a   Handoko, M Louis ^a   Guignabert, Christophe ^b,c   Bogaard, Harm J ^a   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Pulmonary hypertension; Renin angiotensin system; Sympathetic nervous system

Indexed keywords

[1 [(2 DIMETHYLAMINO)ETHYLAMINO] 4 (HYDROXYMETHYL) 7 [(4 METHYLPHENYL)SULFONYLOXY] 9H XANTHENE 9 ONE]; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROHORMONE; NORADRENALIN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; BLOOD VOLUME; DRUG CONTRAINDICATION; DRUG EFFICACY; HEART FUNCTION; HEART OUTPUT; HUMAN; MORTALITY; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SACRAL NERVE STIMULATION; SURVIVAL; UPREGULATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; HEART ATRIA; HUMANS; HYPERTENSION, PULMONARY; NEUROTRANSMITTER AGENTS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84872001689     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201209-1663PP     Document Type: Review

References (50)

1. Handoko ML, de Man FS, Allaart CP, Paulus WJ, Westerhof N, Vonk-Noordegraaf A. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. Eur Respir Rev 2010;19:72-82.
2. Loewi O. Über humorale Übertragbarkeit der Herznervenwirkung. Pflügers Archiv European Journal of Physiology 1924;204:629-640.
3. Guyton A, Hall J. Textbook of medical physiology, 10th ed. Philadelphia: W.B. Saunders; 2000.
4. Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol 2008;75:781-786. (Pubitemid 351174108)
5. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamiezon S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contr.action and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309. (Pubitemid 17178124)
6. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992;102:1407-1412.
7. Leier CV, Bambach D, Nelson S, Hermiller JB, Huss P, Magorien RD, Unverferth DV. Captopril in primary pulmonary hypertension. Circulation 1983;67:155-161. (Pubitemid 13222085)
8. Ikram H, Maslowski AH, Nicholls MG, Espiner EA, Hull FT. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J 1982;48:541-545. (Pubitemid 13217289)
9. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaï ci A, Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
10. van de Veerdonk MC, Kind T, Marcus JT, Mauritz G-J, Heymans MW, Bogaard H-J, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511-2519.
11. Velez-Roa S, Ciarka A, Najem B, Vachiery J-L, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;110:1308-1312. (Pubitemid 39202350)
12. McGowan CL, Swiston JS, Notarius CF, Mak S, Morris BL, Picton PE, Granton JT, Floras JS. Discordance between microneurographic and heart-rate spectral indices of sympathetic activity in pulmonary arterial hypertension. Heart 2009;95:754-758.
13. Wensel R, Jilek C, Dörr M, Francis DP, Stadler H, Lange T, Blumberg F, Opitz C, Pfeifer M, Ewert R. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J 2009;34:895-901.
14. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-1585.
15. Mak S, Witte KK, Al-Hesayen A, Granton JJ, Parker JD. Cardiac sympathetic activation in patients with pulmonary arterial hypertension. Am J Physiol Regul Integr Comp Physiol 2012;302:R1153-R1157.
16. Ciarka A, Vachièry J-L, Houssière A, Gujic M, Stoupel E, Velez-Roa S, Naeije R, van de Borne P. Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension. Chest 2007;131:1831-1837. (Pubitemid 46981642)
17. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1269-1275.
18. Dimopoulos S, Anastasiou-Nana M, Katsaros F, Papazachou O, Tzanis G, Gerovasili V, Pozios H, Roussos C, Nanas J, Nanas S. Impairment of autonomic nervous system activity in patients with pulmonary arterial hypertension: a case control study. J Card Fail 2009;15:882-889.
19. Naeije R, van de Borne P. Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension. Eur Respir J 2009;34:792-794.
20. Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007;29:944-950. (Pubitemid 46711899)
21. Sun XG, Hansen JE, Oudiz RJ,Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001;104:429-435. (Pubitemid 32678273)
22. de Man FS, van Hees HWH, Handoko ML, Niessen HW, Schalij I, Humbert M, Dorfmüller P, Mercier O, Bogaard HJ, Postmus PE, et al. Diaphragm muscle fiber weakness in pulmonary hypertension. Am J Respir Crit Care Med 2011;183:1411-1418.
23. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, et al. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 2003;4:27-30. (Pubitemid 36443383)
24. Chung WK, Deng L, Carroll JS, Mallory N, Diamond B, Rosenzweig EB, Barst RJ, Morse JH. Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant 2009;28:373-379.
25. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 2000;192:379-384.
26. Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, Girgis RE, Hassoun PM. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1364-1369. (Pubitemid 351860914)
27. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, Simonneau G, Fadel E, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:780-789.
28. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, DuguidWP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739. (Pubitemid 23170122)
29. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-307. (Pubitemid 29356368)
30. Holverda S, Gan CT-J, Marcus JT, Postmus PE, Boonstra A, Vonk-Noordegraaf A. Impaired stroke volume response to exercise in pulmonary arterial hypertension. J Am Coll Cardiol 2006;47:1732-1733.
31. Ishikawa M, Sato N, Asai K, Takano T, Mizuno K. Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J 2009;73:2337-2341.
32. Usui S, Yao A, Hatano M, Kohmoto O, Takahashi T, Nagai R, Kinugawa K. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. Circ J 2006;70:1208-1215. (Pubitemid 44387006)
33. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-660.
34. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012;5:97-105.
35. So PP, Davies RA, Chandy G, Stewart D, Beanlands RSB, Haddad H, Pugliese C, Mielniczuk LM. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 2012;109:1504-1509.
36. Okada M, Harada T, Kikuzuki R, Yamawaki H, Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 2009;111:193-200.
37. Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2005;289:H2319-H2324. (Pubitemid 41698538)
38. Rouleau JL, Kapuku G, Pelletier S, Gosselin H, Adam A, Gagnon C, Lambert C, Meloche S. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 2001;104:939-944. (Pubitemid 32778047)
39. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
40. Maron BA, Zhang Y-Y, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 2012;126:963-974.
41. Yamazato Y, Ferreira AJ, Hong K-H, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009;54:365-371.
42. Johnson JA, West J, Maynard KB, Hemnes AR. ACE2 improves right ventricular function in a pressure overload model. PLoS ONE 2011;6:e20828.
43. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048-1054.
44. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:1482-1489. (Pubitemid 44527003)
45. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJH, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669-675.
46. Handoko ML, de Man FS, Happé CM, Schalij I, Musters RJP, Westerhof N, Postmus PE, Paulus WJ, van der Laarse WJ, Vonk-Noordegraaf A. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009;120:42-49.
47. Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 2012;40:84-92.
48. Peacock A, Ross K. Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents. Thorax 2010;65:454-455.
49. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355. (Pubitemid 26152713)
50. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Glaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.